VolitionRx presented its Capture-Seq™ technology at the ESMO MAP 2026 conference, demonstrating highly accurate early-stage cancer detection using a novel liquid biopsy method. The technology detected 95% of stage I and II cancers in validation studies without false positives, targeting a $36 billion market in early cancer detection and minimal residual disease monitoring. This advancement could significantly improve early cancer diagnosis and patient outcomes if validated in larger trials. VolitionRx is fast-tracking development and patenting this innovative epigenetic approach.
Ahead of Oracle's earnings report, options traders are favoring call options over puts, indicating bullish sentiment and expecting an 11% stock price move. This expectation is influenced by Oracle's history of sharp post-earnings moves, including a n...
Cryptocurrency markets saw a general decline with major coins like Bitcoin dropping 2.03% to $77,737 and Ethereum falling 1.66% to $2,457.87. Other notable cryptocurrencies such as Binance Coin, XRP, and Dogecoin also experienced significant decrease...
Alphabet's shares fell 7.46% over the past month, underperforming the Nasdaq despite strong fundamentals like 24.23% revenue growth and robust AI investments. The company leads in search, video, cloud, and AI, with Google Cloud revenue up 82% year-ov...
XStable, a decentralized trading platform for real-world assets, has integrated with the Sui Network to enable on-chain trading of gold, silver, platinum, and foreign exchange pairs. This expansion beyond Solana adds Sui Wallet support and USDC trans...
On September 8, XRP spot ETFs attracted about $1.55 million in net inflows, making them the only crypto ETFs to see daily gains. In contrast, ETFs for Bitcoin, Ethereum, Solana, and Hyperliquid experienced net withdrawals on the same day. This highli...
